# Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy

> **NCT00932282** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 13 (actual)

## Conditions studied

- Peanut Hypersensitivity

## Interventions

- **DRUG:** Peanut Oral Immunotherapy
- **DRUG:** Omalizumab

## Key facts

- **NCT ID:** NCT00932282
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2018-03-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00932282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00932282, "Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00932282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*